Basch EM, Deal AM, Dueck AC, et al. Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. J Clin Oncol. 35, 2017 (suppl; abstr LBA2).
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker